Loading [Contrib]/a11y/accessibility-menu.js
JHEOR
  • Menu
  • Articles
    • Author Correction
    • Autoimmune Diseases
    • Cardiovascular Conditions
    • Commentary
    • Dermatological Diseases
    • Endocrine Diseases
    • Gastrointestinal Conditions
    • General Indications
    • Hematology
    • Hereditary Genetic Disorders
    • Infectious Diseases
    • Methodology and Healthcare Policy
    • Nephrologic/Hepatologic Conditions
    • Neurological Diseases
    • Oncology
    • Ophthalmology
    • Other Conditions
    • Psychological Conditions
    • Respiratory Diseases
    • Trauma Induced Conditions
    • Urological/Gynecological Diseases
    • All
  • For Authors
  • Editorial Board
  • About
  • Issues
  • Blog
  • Journal Policies
  • For Reviewers
  • search

    Sorry, something went wrong. Please try your search again.
    ×

    • Articles
    • Blog posts

RSS Feed

Enter the URL below into your favorite RSS reader.

https://jheor.org/feed
×
Oncology
Vol. 4, Issue 2, 2017 October 26, 2016 EDT

A Cost-effectiveness Analysis of Brentuximab Vedotin in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

Margaret Hux , Denise Zou , Esprit Ma , Peter Sajosi , Andreas Engstrom , Ross Selby , Eugene Benson , Andrew Briggs , Vijayveer Bonthapally ,
  • incremental cost-effectiveness ratio
  • quality-adjusted life year
  • chemotherapy
  • systemic anaplastic large cell lymphoma
  • brentuximab vedotin
  • cost-effectiveness
ccby-4.0 • https://doi.org/10.36469/9820
JHEOR
1.
Hux M, Zou D, Ma E, et al. A Cost-effectiveness Analysis of Brentuximab Vedotin in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma. JHEOR. 2016;4(2):188-203. doi:10.36469/9820
Save article as...▾
  • PDF
  • XML
  • Citation (BibTeX)
Powered by Scholastica, the modern academic journal management system